Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Sunepitron

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Sunepitron
Clinical data
Other namesCP-93,393
Routes of
administration
Oral
ATC code
  • none
Identifiers
  • 1-{[2-(pyrimidin-2-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl}pyrrolidine-2,5-dione
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H23N5O2
Molar mass329.404 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)CC1)CC4CCC3N(CCN(c2ncccn2)C3)C4

Sunepitron (developmental code nameCP-93,393) is a combined5-HT1A receptoragonist andα2-adrenergic receptorantagonist.[1][2] It was previously under development byPfizer for the treatment ofdepression andanxiety.[3] It made it tophase IIIclinical trials before being discontinued.[2][3]

Chemistry

[edit]

Synthesis

[edit]
Sunepitron synthesis: G.N. Bright, K.A. Desai,U.S. patent 5,122,525 (1992).

The synthesis starts by conversion of the pyridine dicarboxylic acid (1) to its acid chloride; rxn with MeOH then affords the ester (2).Catalytic hydrogenation serves to reduce the pyridine ring to a piperidine of undefined stereochemistry (3). Alkylation of this intermediate withchloroacetonitrile affords (4). Treatment of that intermediate withRaney nickel reduces the cyano group to the corresponding primary amine; this product then undergoes an internal ester-amine interchange to yield the cyclizedlactam (5). LAH serves to reduce the lactam to an amine; the ester on the other ring is reduced to a carbinol in the process, affording the aminoalcohol (7). The basic function is next alkylated with 2-chloropyrimidine (7). Rxn of the alcoholin (8) with MsCl leads to the mesylate; that group is next displaced bysodium azide (9); the azide group is next reduced to the primary amine. Resolution of this product as itsmandelate salt then yields (10) as a single enantiomer. Rxn of that product withsuccinic anhydride converts the pendant amine to a succinimide, affording the anxiolytic agentsunepitron (1).

See also

[edit]

References

[edit]
  1. ^Goodnick PJ (July 1999). "Psychopharmacology of depression in the next millennium".CNS Spectrums.4 (7):21–35.doi:10.1017/s1092852900011998.PMID 18438295.S2CID 28460185.
  2. ^abStahl SM (2000).Essential psychopharmacology: neuroscientific basis and practical application. Cambridge, UK: Cambridge University Press. p. 265.ISBN 0-521-64615-4.
  3. ^abKaplan EP, Turkington C (2001).Making the antidepressant decision: how to choose the right treatment option for you and your loved ones. Chicago, Ill: Contemporary Books.ISBN 0-7373-0417-0.
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Miscellaneous
5-HT1ARTooltip 5-HT1A receptoragonists
GABAARTooltip GABAA receptorPAMsTooltip positive allosteric modulators
Gabapentinoids
(α2δVDCCblockers)
Antidepressants
Sympatholytics
(Antiadrenergics)
Others
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sunepitron&oldid=1268894910"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp